Labcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted

Dow Jones

2025/10/28

By Rob Curran

Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services.

The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier.

Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet.

Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet.

Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50.

The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts.

Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

October 28, 2025 07:15 ET (11:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2578958021"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578958021\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578958021?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578958021","market":"us","top_or_hot":-1,"title":"Labcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services. \n</p>\n<p>\n  The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet. \n</p>\n<p>\n  Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. \n</p>\n<p>\n  The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts. \n</p>\n<p>\n  Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:15 ET (11:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp 3Q Net Income, Revenue Up, 2025 Adj EPS View Boosted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-28 19:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services. \n</p>\n<p>\n  The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet. \n</p>\n<p>\n  Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. \n</p>\n<p>\n  The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts. \n</p>\n<p>\n  Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:15 ET (11:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578958021","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578958021","pubTimestamp":1761650100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services.The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier.Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet.Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet.Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50.The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts.Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","BK4196":"保健护理服务","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LH":"徕博科","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD"},"translate_title":"Labcorp第三季度净利润、收入增长，2025年调整后每股收益预期增强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":0.9},"content_text":"By Rob Curran \n\n\n \n\n\n  Labcorp Holdings' third-quarter net income and revenue rose and the company boosted its adjusted earnings growth forecast on strong demand for its blood tests and other laboratory services. \n\n\n  The Burlington, N.C., lab-services company logged earnings of $261.1 million, or $3.12 a share, up from $169.3 million, or $2 a share, a year earlier. \n\n\n  Stripping out certain one-time items, Labcorp posted adjusted earnings of $4.18 a share, exceeding the mean analyst target of $3.94 a share, as per FactSet. \n\n\n  Revenue rose 8.6% to $3.56 billion, in line with the average Wall Street peg, as per FactSet. \n\n\n  Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. \n\n\n  The diagnostic testing company cut its revenue growth projection for the year to a range of 7.4% to 8% from 7.5% to 8.6% previously, to reflect currency and acquisition shifts. \n\n\n  Recently, Labcorp Holdings recently said it would begin selling a Roche Holding blood test for diagnosing Alzheimer's disease in primary-care settings in 2026. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 07:15 ET (11:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}